Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Policy / Regulatory

Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan

Fineline Cube Jan 23, 2024

The General Office of the CPC Central Committee and State Council has released the “Implementation...

Company Drug

AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment

Fineline Cube Jan 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...

Company Drug

Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial

Fineline Cube Jan 23, 2024

Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...

Policy / Regulatory

NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions

Fineline Cube Jan 23, 2024

The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...

Company Deals

Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine

Fineline Cube Jan 23, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...

Company Deals

Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements

Fineline Cube Jan 23, 2024

Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...

Company Deals

Digital Precision Medicine Secures Over $28 Million in Series C Financing

Fineline Cube Jan 22, 2024

Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...

Company Drug

NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin

Fineline Cube Jan 22, 2024

The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...

Company Drug

Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs

Fineline Cube Jan 22, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...

Company Drug

AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial

Fineline Cube Jan 22, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...

Company Drug

J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment

Fineline Cube Jan 22, 2024

The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...

Policy / Regulatory

Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth

Fineline Cube Jan 22, 2024

Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...

Company

Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches

Fineline Cube Jan 22, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...

Company Drug

Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis

Fineline Cube Jan 22, 2024

Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...

Company Deals

Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines

Fineline Cube Jan 22, 2024

Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...

Company Deals R&D

Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI

Fineline Cube Jan 22, 2024

Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent

Fineline Cube Jan 22, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...

Company

HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province

Fineline Cube Jan 22, 2024

HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...

Company Deals Digital R&D

AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics

Fineline Cube Jan 22, 2024

Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...

Company Drug

InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA

Fineline Cube Jan 22, 2024

InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...

Posts pagination

1 … 347 348 349 … 602

Recent updates

  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.